WO2019176996A1 - 輸液製剤 - Google Patents
輸液製剤 Download PDFInfo
- Publication number
- WO2019176996A1 WO2019176996A1 PCT/JP2019/010195 JP2019010195W WO2019176996A1 WO 2019176996 A1 WO2019176996 A1 WO 2019176996A1 JP 2019010195 W JP2019010195 W JP 2019010195W WO 2019176996 A1 WO2019176996 A1 WO 2019176996A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infusion
- chamber
- chamber infusion
- acid
- preparation
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 100
- 150000001413 amino acids Chemical class 0.000 claims abstract description 63
- 150000007524 organic acids Chemical class 0.000 claims abstract description 47
- 230000003139 buffering effect Effects 0.000 claims abstract description 25
- 239000011575 calcium Substances 0.000 claims abstract description 22
- 239000002960 lipid emulsion Substances 0.000 claims abstract description 22
- 238000005192 partition Methods 0.000 claims abstract description 22
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 17
- 239000003792 electrolyte Substances 0.000 claims abstract description 17
- 238000004891 communication Methods 0.000 claims abstract description 12
- 238000001802 infusion Methods 0.000 claims description 346
- 239000011259 mixed solution Substances 0.000 claims description 41
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000003995 emulsifying agent Substances 0.000 claims description 24
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 5
- 239000000203 mixture Substances 0.000 abstract description 25
- 239000007788 liquid Substances 0.000 abstract description 14
- 238000003860 storage Methods 0.000 abstract description 12
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 58
- 235000001014 amino acid Nutrition 0.000 description 58
- 238000002156 mixing Methods 0.000 description 55
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 30
- 235000021588 free fatty acids Nutrition 0.000 description 22
- 239000003925 fat Substances 0.000 description 19
- 235000019197 fats Nutrition 0.000 description 19
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 18
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 18
- 229960002885 histidine Drugs 0.000 description 17
- 239000003921 oil Substances 0.000 description 16
- 235000019198 oils Nutrition 0.000 description 16
- 235000000346 sugar Nutrition 0.000 description 16
- 239000003978 infusion fluid Substances 0.000 description 15
- 229960005069 calcium Drugs 0.000 description 14
- 238000004519 manufacturing process Methods 0.000 description 14
- 229940088594 vitamin Drugs 0.000 description 13
- 229930003231 vitamin Natural products 0.000 description 13
- 235000013343 vitamin Nutrition 0.000 description 13
- 239000011782 vitamin Substances 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 12
- 230000003204 osmotic effect Effects 0.000 description 12
- 229910052698 phosphorus Inorganic materials 0.000 description 12
- 239000011574 phosphorus Substances 0.000 description 12
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 230000007774 longterm Effects 0.000 description 11
- -1 medium chain fatty acid triglycerides Chemical class 0.000 description 11
- 239000011591 potassium Substances 0.000 description 11
- 229960003975 potassium Drugs 0.000 description 11
- 229910052700 potassium Inorganic materials 0.000 description 11
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 10
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 10
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 10
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 9
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960000304 folic acid Drugs 0.000 description 9
- 235000019152 folic acid Nutrition 0.000 description 9
- 239000011724 folic acid Substances 0.000 description 9
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 8
- 235000015165 citric acid Nutrition 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 8
- 235000002639 sodium chloride Nutrition 0.000 description 8
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000011777 magnesium Substances 0.000 description 7
- 229910052749 magnesium Inorganic materials 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 150000003722 vitamin derivatives Chemical class 0.000 description 7
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 description 6
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 6
- 238000011049 filling Methods 0.000 description 6
- 229940093915 gynecological organic acid Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 229960003512 nicotinic acid Drugs 0.000 description 6
- 235000001968 nicotinic acid Nutrition 0.000 description 6
- 239000011664 nicotinic acid Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 235000005985 organic acids Nutrition 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 235000019155 vitamin A Nutrition 0.000 description 6
- 239000011719 vitamin A Substances 0.000 description 6
- 229940045997 vitamin a Drugs 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 5
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 5
- 229930064664 L-arginine Natural products 0.000 description 5
- 235000014852 L-arginine Nutrition 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 229930182844 L-isoleucine Natural products 0.000 description 5
- 235000019454 L-leucine Nutrition 0.000 description 5
- 239000004395 L-leucine Substances 0.000 description 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 5
- 229930195722 L-methionine Natural products 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 239000004473 Threonine Substances 0.000 description 5
- 229930003270 Vitamin B Natural products 0.000 description 5
- 229930003316 Vitamin D Natural products 0.000 description 5
- 229930003427 Vitamin E Natural products 0.000 description 5
- 229930003448 Vitamin K Natural products 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 229910052801 chlorine Inorganic materials 0.000 description 5
- 229960002433 cysteine Drugs 0.000 description 5
- 238000004945 emulsification Methods 0.000 description 5
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 5
- 229960002989 glutamic acid Drugs 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 229960003136 leucine Drugs 0.000 description 5
- 229960003646 lysine Drugs 0.000 description 5
- 229960004452 methionine Drugs 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229940055726 pantothenic acid Drugs 0.000 description 5
- 235000019161 pantothenic acid Nutrition 0.000 description 5
- 239000011713 pantothenic acid Substances 0.000 description 5
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 229960002898 threonine Drugs 0.000 description 5
- 229960004295 valine Drugs 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Substances 0.000 description 5
- 235000019166 vitamin D Nutrition 0.000 description 5
- 239000011710 vitamin D Substances 0.000 description 5
- 150000003710 vitamin D derivatives Chemical class 0.000 description 5
- 235000019165 vitamin E Nutrition 0.000 description 5
- 229940046009 vitamin E Drugs 0.000 description 5
- 239000011709 vitamin E Substances 0.000 description 5
- 235000019168 vitamin K Nutrition 0.000 description 5
- 239000011712 vitamin K Substances 0.000 description 5
- 150000003721 vitamin K derivatives Chemical class 0.000 description 5
- 229940046008 vitamin d Drugs 0.000 description 5
- 229940046010 vitamin k Drugs 0.000 description 5
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 4
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 4
- 235000019766 L-Lysine Nutrition 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 4
- 235000013878 L-cysteine Nutrition 0.000 description 4
- 229930182821 L-proline Natural products 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229930003268 Vitamin C Natural products 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 229960003767 alanine Drugs 0.000 description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 4
- 229960005261 aspartic acid Drugs 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000787 lecithin Substances 0.000 description 4
- 235000010445 lecithin Nutrition 0.000 description 4
- 229940067606 lecithin Drugs 0.000 description 4
- 239000001630 malic acid Substances 0.000 description 4
- 235000011090 malic acid Nutrition 0.000 description 4
- 229940101267 panthenol Drugs 0.000 description 4
- 235000020957 pantothenol Nutrition 0.000 description 4
- 239000011619 pantothenol Substances 0.000 description 4
- 235000016236 parenteral nutrition Nutrition 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 229960002429 proline Drugs 0.000 description 4
- 235000008160 pyridoxine Nutrition 0.000 description 4
- 239000011677 pyridoxine Substances 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 235000019192 riboflavin Nutrition 0.000 description 4
- 239000002151 riboflavin Substances 0.000 description 4
- 229960001153 serine Drugs 0.000 description 4
- 229960003495 thiamine Drugs 0.000 description 4
- 229960004441 tyrosine Drugs 0.000 description 4
- 235000019154 vitamin C Nutrition 0.000 description 4
- 239000011718 vitamin C Substances 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 229940011671 vitamin b6 Drugs 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000004135 Bone phosphate Substances 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 3
- 229940123973 Oxygen scavenger Drugs 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 235000000639 cyanocobalamin Nutrition 0.000 description 3
- 239000011666 cyanocobalamin Substances 0.000 description 3
- 229960002104 cyanocobalamin Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- CHFUHGDBYUITQJ-UHFFFAOYSA-L dipotassium;2,3-dihydroxypropyl phosphate Chemical compound [K+].[K+].OCC(O)COP([O-])([O-])=O CHFUHGDBYUITQJ-UHFFFAOYSA-L 0.000 description 3
- 239000008344 egg yolk phospholipid Substances 0.000 description 3
- 229940068998 egg yolk phospholipid Drugs 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 235000014593 oils and fats Nutrition 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 239000011772 phylloquinone Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011600 potassium glycerophosphate Substances 0.000 description 3
- 235000000491 potassium glycerophosphate Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- 235000005282 vitamin D3 Nutrition 0.000 description 3
- 239000011647 vitamin D3 Substances 0.000 description 3
- 229940021056 vitamin d3 Drugs 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- BTLPCOOVNVTENY-UHFFFAOYSA-N 8L8 Natural products CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCCC=CCC=CCCCCC BTLPCOOVNVTENY-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 229960002713 calcium chloride Drugs 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000011147 magnesium chloride Nutrition 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 229960002816 potassium chloride Drugs 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229960002901 sodium glycerophosphate Drugs 0.000 description 2
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- REULQIKBNNDNDX-UHFFFAOYSA-M sodium;2,3-dihydroxypropyl hydrogen phosphate Chemical compound [Na+].OCC(O)COP(O)([O-])=O REULQIKBNNDNDX-UHFFFAOYSA-M 0.000 description 2
- 239000002195 soluble material Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- SNNIXEGBYLWWHH-DFWYDOINSA-N (2s)-2,5-diamino-5-oxopentanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCC(N)=O SNNIXEGBYLWWHH-DFWYDOINSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- OCJAHRQBZPOWQF-LTXDKZCQSA-N 1,3-di(decanoyloxy)propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC OCJAHRQBZPOWQF-LTXDKZCQSA-N 0.000 description 1
- BTLPCOOVNVTENY-NFYLBXPESA-N 1,3-di(octanoyloxy)propan-2-yl (9z,12z)-octadeca-9,12-dienoate Chemical compound CCCCCCCC(=O)OCC(COC(=O)CCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC BTLPCOOVNVTENY-NFYLBXPESA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- ALZVPLKYDKJKQU-XVKPBYJWSA-N Ala-Tyr Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ALZVPLKYDKJKQU-XVKPBYJWSA-N 0.000 description 1
- XTWSWDJMIKUJDQ-RYUDHWBXSA-N Arg-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XTWSWDJMIKUJDQ-RYUDHWBXSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 244000146493 Cryptotaenia japonica Species 0.000 description 1
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 208000034767 Hypoproteinaemia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- JXNRXNCCROJZFB-RYUDHWBXSA-O L-tyrosiniumyl-L-arginine(1+) Chemical compound NC(=[NH2+])NCCC[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-O 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- GNMSLDIYJOSUSW-LURJTMIESA-N N-acetyl-L-proline Chemical compound CC(=O)N1CCC[C@H]1C(O)=O GNMSLDIYJOSUSW-LURJTMIESA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- OHSHFZJLPYLRIP-BMZHGHOISA-M Riboflavin sodium phosphate Chemical compound [Na+].OP(=O)([O-])OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O OHSHFZJLPYLRIP-BMZHGHOISA-M 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001125046 Sardina pilchardus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- JAQGKXUEKGKTKX-HOTGVXAUSA-N Tyr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 JAQGKXUEKGKTKX-HOTGVXAUSA-N 0.000 description 1
- 206010047095 Vascular pain Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- RRNJROHIFSLGRA-JEDNCBNOSA-N acetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.NCCCC[C@H](N)C(O)=O RRNJROHIFSLGRA-JEDNCBNOSA-N 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010070783 alanyltyrosine Proteins 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 229910001567 cementite Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ARJXIGOIOGJAKR-LURJTMIESA-N ethyl L-methioninate Chemical compound CCOC(=O)[C@@H](N)CCSC ARJXIGOIOGJAKR-LURJTMIESA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229940013640 flavin mononucleotide Drugs 0.000 description 1
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 1
- 239000011768 flavin mononucleotide Substances 0.000 description 1
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 1
- 229920002457 flexible plastic Polymers 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 210000002977 intracellular fluid Anatomy 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 235000014413 iron hydroxide Nutrition 0.000 description 1
- NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
- 108010053037 kyotorphin Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960005357 lysine acetate Drugs 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- UIHPNZDZCOEZEN-YFKPBYRVSA-N methyl (2s)-2-amino-4-methylsulfanylbutanoate Chemical compound COC(=O)[C@@H](N)CCSC UIHPNZDZCOEZEN-YFKPBYRVSA-N 0.000 description 1
- MWZPENIJLUWBSY-VIFPVBQESA-N methyl L-tyrosinate Chemical compound COC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MWZPENIJLUWBSY-VIFPVBQESA-N 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- UDCIYVVYDCXLSX-SDNWHVSQSA-N n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[(e)-5-hydroxy-3-(propyldisulfanyl)pent-2-en-2-yl]formamide Chemical compound CCCSS\C(CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N UDCIYVVYDCXLSX-SDNWHVSQSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- PHZLMBHDXVLRIX-UHFFFAOYSA-M potassium lactate Chemical compound [K+].CC(O)C([O-])=O PHZLMBHDXVLRIX-UHFFFAOYSA-M 0.000 description 1
- 235000011085 potassium lactate Nutrition 0.000 description 1
- 239000001521 potassium lactate Substances 0.000 description 1
- 229960001304 potassium lactate Drugs 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229950007142 prosultiamine Drugs 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229960003010 sodium sulfate Drugs 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 1
- 108010003137 tyrosyltyrosine Proteins 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
- A61J1/20—Arrangements for transferring or mixing fluids, e.g. from vial to syringe
- A61J1/2093—Containers having several compartments for products to be mixed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to an infusion preparation containing fat, amino acid, and electrolyte. More specifically, the present invention relates to an infusion preparation containing a two-chamber container, in which a sugar and a fat emulsion are accommodated in a first chamber and an amino acid and an electrolyte are accommodated in a second chamber.
- PPN peripheral parenteral nutrition
- TPN central parenteral nutrition
- infusion preparations are transported to hospitals and other facilities after distribution and sales after production, and are stored in the facilities until they are actually used clinically.
- These infusion preparations are required to have stability during the period from production to clinical use.
- the stability of the infusion preparation is ensured by clarifying the period during which the stability can be ensured by testing, and setting the expiration date of the infusion preparation so as not to exceed the period.
- An object of the present invention is to provide an infusion preparation in which the generation of insoluble foreign matters after mixing two liquids during long-term storage is suppressed.
- the present inventors have elucidated the cause of the occurrence of such insoluble foreign matters after mixing two liquids through an independent study.
- free fatty acids are generated in the first infusion solution during long-term storage, and insoluble foreign matter is generated due to the presence of the free fatty acids after mixing the two liquids.
- the first chamber infusion contains 0.15 g / L or more of at least one selected from the group consisting of a buffering amino acid, and a divalent organic acid and a trivalent organic acid.
- the present inventors have found that the generation of free fatty acids in the first infusion solution during long-term storage can be suppressed if it is included.
- [Claim 1] It has two chambers separated by a partition that can communicate,
- the first chamber contains a fat emulsion, further contains a buffered amino acid, and a first chamber infusion containing at least one selected from the group consisting of a divalent organic acid and a trivalent organic acid, and a second An infusion preparation containing a second chamber infusion containing at least calcium as an amino acid and an electrolyte in a chamber,
- the total content of the buffering amino acid, the divalent organic acid, and the trivalent organic acid in the first chamber infusion is 0.15 g / L to 0.5 g / L, and 48 hours after the partition communication.
- the infusion preparation wherein the pH of the mixed solution of the first chamber infusion and the second chamber infusion at the time of is 6.53 or less.
- [Section 2] Item 2. The infusion preparation according to Item 1, wherein the fat emulsion contains an emulsifier, and the first chamber infusion contains 0.01 to 2 w / v% of the emulsifier.
- [Section 3] Item 3. The infusion preparation according to Item 1 or 2, wherein the mixed solution of the first chamber infusion and the second chamber infusion after partition communication contains 1 mEq / L or more of Ca 2+ .
- [Claim 4] Item 4.
- the second chamber infusion further comprises at least citric acid as an electrolyte, and the citric acid concentration (mEq) is not less than the calcium concentration (mEq) in the second chamber infusion according to any one of Items 1 to 3.
- Infusion formulation [Section 5] Item 5. The infusion preparation according to any one of Items 1 to 4, wherein the first chamber infusion contains at least histidine as the buffering amino acid.
- Ciim 6 Item 6. The liquid mixture of the first chamber infusion and the second chamber infusion according to any one of Items 1 to 5, obtained by partition communication.
- the generation of insoluble foreign matters after mixing two liquids during long-term storage is suppressed. For this reason, the usable period can be set longer.
- the present invention has two chambers separated by a communicable partition, in which a first chamber infusion containing a fat emulsion is stored in a first chamber, and a second chamber infusion containing an amino acid and an electrolyte is stored in a second chamber.
- a communicable partition in which a first chamber infusion containing a fat emulsion is stored in a first chamber, and a second chamber infusion containing an amino acid and an electrolyte is stored in a second chamber.
- the first chamber infusion used in the present invention contains a fat emulsion, and further contains an amino acid having a buffering property, and at least one selected from the group consisting of a divalent organic acid and a trivalent organic acid. .
- the fat emulsion blended in the first chamber infusion is an oil-in-water emulsion prepared by dispersing fats and oils in water using an emulsifier.
- the fat emulsion can be prepared according to a conventional method. For example, after adding an oil and fat and an emulsifier to water, stirring is performed to prepare a crude emulsion, and then the crude emulsion is emulsified by a conventional method such as a high-pressure emulsification method.
- oils and fats edible oils can be preferably used.
- vegetable oil (soybean oil, olive oil, cottonseed oil, safflower oil, corn oil, palm oil, perilla oil, sesame oil, etc.), fish oil (sardine oil, etc.), medium chain fatty acid triglycerides (triglycerides of fatty acids having 8 to 10 carbon atoms) [Commercial name: “Panasate” (manufactured by NOF Corporation), “ODO” (manufactured by Nissin Oil Co., Ltd.), “Coconard” (manufactured by Kao Corporation), “Miglyol” (Mitsuba Trading Co., Ltd.)], chemically synthesized triglycerides [ 2-linoleoyl-1,3-dioctanoylglycerol (8L8), 2-linoleoyl-1,3-didecanoylglycerol (10L10), etc.] and the
- emulsifier for example, various pharmaceutically acceptable emulsifiers can be used.
- egg yolk phospholipid egg yolk lecithin
- hydrogenated egg yolk phospholipid egg yolk lecithin
- soybean phospholipid soy lecithin
- hydrogenated soybean phospholipid and the like emulsifiers
- nonionic surfactants and the like exemplified. These may be used alone or in combination of two or more.
- oils and fats include soybean oil, and particularly preferred emulsifiers are egg yolk phospholipid (egg yolk lecithin).
- egg yolk lecithin egg yolk lecithin
- lecithin such as egg yolk lecithin
- the ratio of the fats and emulsifiers used in the preparation of the fat emulsion is not particularly limited as long as an oil-in-water fat emulsion is obtained.
- Oils and fats are preferably used in the resulting fat emulsion at a ratio of about 0.5 to 6 w / v%, more preferably about 1 to 5 w / v%.
- the emulsifier is preferably about 0.01 to 2 w / v%, more preferably about 0.1 to 1.5% w / v%, and still more preferably 0.2 to 1.5 w in the resulting fat emulsion. Used at a rate of about / v%.
- the blending ratio of the emulsifier in the first chamber infusion is within this range, combined with other features of the present invention, the generation of free fatty acids during long-term storage is suppressed. Thereby, generation
- One specific example of a method for producing a fat emulsion particularly suitable for the present invention is as follows. That is, oil and fat and an emulsifier are added to water, and at least one selected from glycerin and glucose is added, followed by stirring to prepare a crude emulsion, and then the crude emulsion is emulsified by a conventional method such as a high-pressure emulsification method. .
- a high-pressure emulsification method is adopted, the method is performed, for example, using an emulsifier such as a Manton gorin homogenizer, and the crude emulsion is about 2 to 50 times, preferably about 3 to about 50 to 700 kg / cm 2. It can be performed by passing it about 20 times.
- glycerin and / or glucose may be present at the time of emulsification.
- glycerin and / or glucose may be added to a crude emulsion prepared using an oil and fat and an emulsifier to emulsify. Good.
- the resulting fat emulsion preferably contains about 5 to 70 w / v%, more preferably about 10 to 30 w / v% of glycerin and / or glucose.
- the first chamber infusion further contains at least one selected from the group consisting of amino acids having a buffering property, and divalent organic acids and trivalent organic acids.
- the total content of the buffering amino acid, the divalent organic acid and the trivalent organic acid in the first chamber infusion is 0.15 g / L to 0.5 g / L.
- the total content of buffered amino acids is calculated based on the amount of these amino acids as free amino acids.
- the pH optimum range in which the production of free fatty acids and the like decomposed from fats and oils and emulsifiers is suppressed is preferably 4.5 to 6.5, more preferably 5.0 to 6.5, and still more preferably 5.5 to 6. 5.
- the pH of the first-chamber infusion solution is suppressed within the range by increasing the buffering property of the first-chamber infusion solution in a pH range in which the production of free fatty acids or the like decomposed from fats and oils and emulsifiers is suppressed. If it can do, it will not specifically limit, For example, histidine, lysine, arginine etc. are mentioned.
- the buffering amino acid it is possible to prevent the production of free fatty acids and the like that are decomposed from fats and oils and emulsifiers, and to suppress the decrease in pH of the second chamber infusion over time.
- the amino acid having such a buffering property is preferably L-histidine and L-lysine, more preferably L-histidine, still more preferably only consisting of L-histidine, or L-histidine. Only. Histidine also functions as a pH adjuster.
- the pH of the first chamber infusion is increased by increasing the buffering property of the first chamber infusion in the pH range in which the production of free fatty acids and the like decomposed from fats and oils and emulsifiers is suppressed.
- the divalent organic acid and the trivalent organic acid can prevent generation of free fatty acids and the like that are decomposed and generated from fats and oils and emulsifiers, and can suppress a decrease in pH of the second chamber infusion over time.
- Citric acid, succinic acid, malic acid and tartaric acid also function as pH adjusters.
- the first chamber infusion contains 0.15 g / L or more in total of at least one selected from the group consisting of a buffering amino acid, and a divalent organic acid and a trivalent organic acid.
- the generation of free fatty acids during long-term storage in is suppressed. Thereby, generation
- the first chamber infusion contains 0.2 g / L or more in total amount of at least one selected from the group consisting of an amino acid having a buffering property, and a divalent organic acid and a trivalent organic acid. It is preferable.
- the upper limit of the total content ratio selected from the group consisting of an amino acid having a buffering property, and a divalent organic acid and a trivalent organic acid in the first chamber infusion is, for example, 0.6 g / L. And preferably 0.5 g / L.
- the total content of at least one selected from the group consisting of a buffering amino acid, a divalent organic acid, and a trivalent organic acid in this first room infusion solution is within this range, It is preferable from the viewpoint of preventing coloring in the case of using a reducing sugar such as glucose and glucose.
- the total content of at least one selected from the group consisting of a buffering amino acid, a divalent organic acid, and a trivalent organic acid in the first chamber infusion is 0.15 g / L. ⁇ 0.6 g / L is preferable, and 0.2 g / L to 0.3 g / L is more preferable.
- various additives known to be added and blended in the fat emulsion can be further blended.
- the additive include a pH adjuster.
- the pH adjuster those known as infusion preparations can be used.
- organic acids and amino acids can be used in addition to acids such as hydrochloric acid and alkalis such as sodium hydroxide and potassium hydroxide.
- examples of the organic acid include acetic acid and lactic acid.
- Examples of amino acids include L-lysine and the like.
- the oil-soluble material can be used by being mixed in advance with the oil component constituting the emulsion.
- the water-soluble material can be mixed with water for injection or added and incorporated into the aqueous phase of the resulting fat emulsion.
- additive compounding amounts can be set as appropriate, and may be the same as those conventionally known additive compounding amounts, for example.
- the blending ratio of the fat emulsion in the first chamber infusion is, for example, 0.5 to 6 w / v%, preferably 1 to 5 w / v%, more preferably 2 to 5 w / v% in terms of the amount of fats and oils.
- the amount of the fat emulsion in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 0.25 to 6 w / v%, preferably 0.5 to It is 3 w / v%, more preferably 1 to 2.5 w / v%.
- the pH of the first chamber infusion is preferably 4.5 to 6.5, more preferably 5.0 to 6.5, and still more preferably 5.5 to 6.5. Within this pH range, in the first chamber infusion suppresses the generation of such free fatty acids to produce decomposition of fats and emulsifiers, and can be stabilized fat emulsion and vitamin B 1.
- the pH adjustment of the first chamber infusion can be performed using a pH adjuster.
- the aforementioned L-histidine and L-arginine, as well as malic acid, citric acid, succinic acid and tartaric acid can be used as pH adjusters, and hydrochloric acid, acetic acid, lactic acid, sodium hydroxide, potassium hydroxide and the like can be used. You may use as a regulator.
- sugar to the first chamber infusion it is desirable to add sugar to the first chamber infusion.
- the sugar to be blended include reducing sugars such as glucose, fructose and maltose, and non-reducing sugars such as xylitol, sorbitol and glycerin.
- reducing sugars such as glucose, fructose and maltose
- non-reducing sugars such as xylitol, sorbitol and glycerin.
- reducing sugars such as glucose, fructose and maltose
- non-reducing sugars such as xylitol, sorbitol and glycerin.
- the mixing ratio of sugar in the first chamber infusion is preferably 70 to 150 g / L.
- the sugar concentration in the mixed solution of the first chamber infusion and the second chamber infusion obtained by partition communication is preferably 50 to 100 g / L, more preferably 50 to 75 g / L.
- first chamber infusion compounding vitamin B 1 As vitamin B 1 blended in the first chamber infusion, thiamine chloride hydrochloride, thiamine nitrate, prosultiamine, octothiamine and the like can be used.
- the mixing ratio of the vitamin B 1 in the first chamber infusion is a thiamine amount conversion, for example, 1.5 ⁇ 10 mg / L, preferably 2 ⁇ 8mg / L. Further, in the infusion preparation of the present invention, vitamin B 1 in the first chamber infusion and mixture of the second chamber infusion obtained by the partition communicating concentration in thiamine amount conversion, preferably 1 ⁇ 6 mg / L, more preferably 1.5-4 mg / L.
- the titratable acidity is preferably 10 or less.
- the titratable acidity is the amount of mL of a 0.1 mol / L sodium hydroxide solution necessary to neutralize 100 mL of the solution to pH 7.4.
- the solvent for the first chamber infusion it is usually possible to use distilled water for injection.
- the amount of the first chamber infusion is appropriately set according to the total amount of the infusion preparation, the amount of the second chamber infusion, and the like.
- the first chamber infusion can be substantially free of potassium. “Substantially not containing potassium” means that a compound containing potassium is not blended. Moreover, it is preferable that the first chamber infusion substantially does not contain calcium. “Substantially free of calcium” means that a compound containing calcium is not blended.
- the osmotic pressure ratio of the first chamber infusion is about 2.0 to 4.0, preferably about 2.0 to 3.5.
- the osmotic pressure ratio is a ratio to the osmotic pressure of physiological saline (that is, a relative ratio when the osmotic pressure of physiological saline is 1).
- the osmotic pressure ratio of infusion refers to the ratio of physiological saline to the osmotic pressure unless otherwise specified.
- the second chamber infusion used in the present invention contains calcium as an amino acid and an electrolyte.
- amino acid blended in the second chamber infusion any amino acid may be used as long as it is used for amino acid infusion for the purpose of supplementing the living body.
- the amino acid is usually used in the form of a free amino acid, but may be in the form of a pharmaceutically acceptable salt, ester, N-acyl derivative or dipeptide.
- free amino acids to be blended in the second chamber infusion include L-leucine, L-isoleucine, L-valine, L-lysine, L-threonine, L-tryptophan, L-methionine, L-phenylalanine, L- Examples include cysteine, L-tyrosine, L-arginine, L-histidine, L-alanine, L-proline, L-serine, glycine, L-aspartic acid, L-glutamic acid and the like.
- amino acid salts include inorganic acid salts such as L-arginine hydrochloride, L-cysteine hydrochloride, L-glutamine hydrochloride, L-histidine hydrochloride, L-lysine hydrochloride; Examples include organic acid salts such as lysine acetate and L-lysine malate.
- amino acid ester include L-tyrosin methyl ester, L-methionine methyl ester, L-methionine ethyl ester, and the like.
- N-acyl forms of amino acids include N-acetyl-L-cysteine, N-acetyl-L-tryptophan, N-acetyl-L-proline and the like.
- amino acid dipeptides include L-tyrosyl-L-tyrosine, L-alanyl-L-tyrosine, L-arginyl-L-tyrosine, L-tyrosyl-L-arginine and the like.
- L-cysteine is preferably formulated as acetylcysteine from the viewpoint of stability.
- These amino acids may be used alone or in combination of two or more from the viewpoint of nutritional supplementation.
- At least all the essential amino acids that is, 9 kinds of L-leucine, L-isoleucine, L-valine, L-lysine, L-threonine, L-tryptophan, L-methionine, L-phenylalanine, L-histidine
- Amino acids are included.
- the mixing ratio of amino acids in the second chamber infusion is preferably 40 to 120 g / L, more preferably 50 to 100 g / L as the total amount of free amino acids.
- the concentration of amino acids in the mixed solution of the first chamber infusion and the second chamber infusion is preferably 10 to 50 g / L, more preferably 20 to 40 g / L as the total amount of free amino acids. is there.
- a suitable example of the combination of amino acids blended in the second chamber infusion and the blending ratio is as follows. That is, in terms of free amino acids, L-leucine: 5 to 15 g / L, L-isoleucine: 3 to 9 g / L, L-valine: 3 to 9 g / L, L-lysine: 3 to 12 g / L, L-threonine : 1.2 to 6 g / L, L-tryptophan: 0.3 to 3 g / L, L-methionine: 0.6 to 4.8 g / L, L-phenylalanine: 1.8 to 9 g / L, L-cysteine : 0.1 to 1.8 g / L, L-tyrosine: 0.06 to 1.2 g / L, L-arginine: 3 to 12 g / L, L-histidine: 1.2 to 6 g / L, L-alanine : 3-9 g / L, L-
- a preferred example of the amino acid concentration in the mixed solution of the first chamber infusion and the second chamber infusion is as follows. That is, in terms of free amino acid, L-leucine: 3 to 9 g / L, L-isoleucine: 1.5 to 4.5 g / L, L-valine: 1.5 to 4.5 g / L, L-lysine: 1 0.5-5 g / L, L-threonine: 0.6-3 g / L, L-tryptophan: 0.15-1.5 g / L, L-methionine: 0.3-2.4 g / L, L-phenylalanine : 0.85 to 4.5 g / L, L-cysteine: 0.03 to 0.9 g / L, L-tyrosine: 0.03 to 0.6 g / L, L-arginine: 1.5 to 5 g / L L-histidine: 0.6-3 g / L, L-alanine: 1.5-4.5
- the electrolyte blended in the second chamber infusion is an electrolyte used in the field of infusion, meaning that it is an active ingredient, not an additive, etc.
- a body fluid for example, blood, intracellular fluid
- body fluid electrolyte body fluid electrolyte
- potassium, calcium, sodium, magnesium, phosphorus, zinc, chlorine and the like are exemplified.
- these electrolytes are preferably not blended in the first chamber infusion.
- potassium is usually compounded in both infusions in the two-chamber infusion preparation to avoid the danger of administration of high-concentration potassium, but in the infusion preparation of the present invention, it is blended only in the second-chamber infusion.
- Examples of calcium supply sources include calcium salts such as calcium gluconate, calcium chloride, calcium glycerophosphate, calcium lactate, calcium pantothenate, and calcium acetate.
- the calcium salt may be in a hydrate form (for example, calcium gluconate hydrate).
- Calcium is blended so that the concentration in the second chamber infusion is preferably 1 or more, more preferably 6 to 12 mEq / L.
- the calcium concentration in the mixed solution of the first chamber infusion and the second chamber infusion is 1 or more, preferably 1 or more and 9 mEq / L or less, more preferably 3 to 6 mEq / L.
- potassium supply source examples include potassium chloride, potassium acetate, potassium citrate, potassium glycerophosphate, potassium sulfate, and potassium lactate.
- potassium glycerophosphate is preferable because it also serves as a phosphorus supply source.
- These potassium sources may be in hydrate form.
- Potassium is preferably blended so that the concentration in the second chamber infusion is 40 mEq / L or less (preferably 25 to 40 mEq / L).
- the potassium concentration in the mixed solution of the first chamber infusion and the second chamber infusion is preferably 16 mEq / L or more, more preferably 16 to 25 mEq / L, still more preferably 16 to 20 mEq / L.
- sodium supply source examples include sodium salts such as sodium chloride, sodium lactate, sodium acetate, sodium sulfate, sodium glycerophosphate, sodium citrate, and sodium lactate.
- sodium citrate may be used as a (part of) sodium source in order to prevent these from causing precipitation. desirable.
- the sodium source may also be in hydrate form.
- the mixing ratio of sodium in the second chamber infusion is, for example, 50 to 100 mEq / L, preferably 40 to 80 mEq / L in the second chamber infusion.
- the concentration of sodium in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 25 to 50 mEq / L, preferably 30 to 40 mEq / L.
- magnesium supply sources include magnesium sulfate, magnesium chloride, and magnesium acetate.
- the magnesium source may also be in hydrate form.
- the mixing ratio of magnesium in the second chamber infusion is preferably 1 to 20 mEq / L, more preferably 5 to 15 mEq / L in the second chamber infusion.
- the magnesium concentration in the mixed solution of the first chamber infusion and the second chamber infusion is preferably 0.5 to 10 mEq / L, more preferably 2 to 6 mEq / L.
- the phosphorus supply source when an inorganic salt is used, precipitation of calcium phosphate or magnesium phosphate may occur. Therefore, organic salts such as sodium glycerophosphate and potassium glycerophosphate are preferably used.
- the lecithin when lecithin is used as an emulsifier in the first chamber, the lecithin is also a phosphorus supply source.
- the mixing ratio of phosphorus to the second chamber infusion is, for example, 0 to 20 mmol / L in the second chamber infusion.
- the concentration of phosphorus in the mixed solution of the first chamber infusion and the second chamber infusion is preferably 1 to 20 mmol / L, more preferably 5 to 10 mmol / L.
- the zinc supply source examples include zinc sulfate and zinc chloride.
- the zinc source may also be in hydrate form.
- the blending ratio of zinc in the second chamber infusion is, for example, 2.5 to 15 ⁇ mol / L in the second chamber infusion.
- the zinc concentration in the mixed solution of the first chamber infusion and the second chamber infusion is preferably 1.5 to 9 ⁇ mol / L.
- chlorine supply sources include sodium chloride, potassium chloride, magnesium chloride, and calcium chloride.
- the mixing ratio of chlorine to the second chamber infusion is, for example, 50 to 100 mEq / L, preferably 40 to 80 mEq / L in the second chamber infusion.
- the concentration of chlorine in the mixed solution of the first chamber infusion and the second chamber infusion is preferably 25 to 60 mEq / L, more preferably 30 to 40 mEq / L.
- the pH can be adjusted to 6.0 to 6.8, preferably 6.2 to 6.7 with a pH adjuster as necessary.
- a pH adjuster the same one as described for the first chamber infusion can be used.
- the second chamber infusion contains at least one dibasic acid and / or tribasic acid selected from the group consisting of citric acid, malic acid and succinic acid, so that impurities or decomposition products of glycerophosphoric acid are contained. Precipitation of calcium phosphate when certain phosphoric acid is generated can be suppressed.
- citric acid is particularly preferable.
- the total concentration (mEq) of dibasic acid and tribasic acid contained in the second chamber infusion is preferably not less than the calcium concentration (mEq).
- distilled water for injection can usually be used as the solvent for the second chamber infusion.
- the osmotic pressure ratio of the second chamber infusion is about 2.0 to 3.5, preferably about 2.0 to 3.0.
- a stabilizer may be added to the infusion preparation of the present invention.
- sulfites such as sodium hydrogensulfite
- sulfites such as sodium hydrogensulfite
- the sulfite is blended in the second chamber infusion in order to avoid the decomposition of vitamin B1 contained in the first chamber infusion.
- the blending amount of sulfite in the second chamber infusion is, for example, 20 to 100 mg / L.
- the infusion preparation of the present invention can be blended a variety of vitamins other than vitamin B 1.
- vitamins include water-soluble vitamins and fat-soluble vitamins.
- the fat-soluble vitamin is blended in the first chamber infusion.
- the water-soluble vitamin may be blended in either the first chamber infusion or the second chamber infusion.
- vitamin B 1 represents are incorporated into the first chamber infusion.
- Examples of water-soluble vitamins blended in the infusion preparation of the present invention include vitamin B group and vitamin C.
- vitamin B group vitamin B 1 (thiamine), vitamin B 2 (riboflavin), vitamin B 3 (niacin), vitamin B 5 (pantothenic acid), vitamin B 6 , vitamin B 7 (biotin), vitamin B 9 (folic acid), vitamin B 12 (cyanocobalamin) and the like.
- the fat-soluble vitamin include vitamin A, vitamin D (particularly cholecalciferol), vitamin E, vitamin K, and the like.
- vitamin C ascorbic acid
- the blending ratio of vitamin C in the second chamber infusion is, for example, 50 to 500 mg / L, preferably 100 to 400 mg / L.
- the concentration of vitamin C in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 25 to 250 mg / L, preferably 50 to 200 mg / L, more preferably 40 to 100 mg / L. L.
- the vitamin B 2 it is possible to use riboflavin, sodium riboflavin phosphate ester, flavin mononucleotide, and the like.
- it can be incorporated into either or both of the first chamber infusion and the second chamber infusion.
- vitamin B 2 is desirably blended in the second chamber infusion.
- the blending ratio of vitamin B 2 in the second chamber infusion is, for example, 2.5 to 15 mg / L, preferably 4 to 8 mg / L as riboflavin.
- the concentration of vitamin B 2 in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 0.5 to 10 mg / L, preferably 0.5 to 3 mg / L as riboflavin. It is.
- the vitamin B 6, can be used pyridoxine, pyridoxine, such as pyridoxine hydrochloride salt.
- vitamin B 6 When vitamin B 6 is blended, it can be blended in one or both of the first chamber infusion and the second chamber infusion, but vitamin B 6 becomes very unstable to light when coexisting with vitamin B 2 since it is preferable to blend different person from the vitamin B 2.
- the proportion of vitamin B 6 in the first chamber infusion is, for example, 2 to 10 mg / L, preferably 2.5 to 6 mg / L as pyridoxine.
- the concentration of vitamin B 6 in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 1-10 mg / L, preferably 1.5-4.5 mg / L as pyridoxine. It is.
- the blending ratio of folic acid in the first chamber infusion is, for example, 0.1 to 0.8 mg / L, preferably 0.2 to 0.6 mg / L.
- the concentration of folic acid in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 0.1 to 0.7 mg / L, preferably 0.2 to 0.4 mg / L. is there.
- the vitamin B 12 can be used cyanocobalamin, acetate hydroxocobalamin, methylcobalamin and the like.
- formulating vitamin B 12 can be incorporated into either or both of the first chamber infusion and the second chamber infusion, when formulating the sulfite into the second chamber is preferably blended in the first chamber infusion .
- the blending ratio of vitamin B 12 in the first chamber infusion is, for example, 2 to 10 ⁇ g / L, preferably 2.5 to 6 ⁇ g / L.
- the concentration of vitamin B 12 in the first chamber infusion and a mixture of the second chamber infusion for example 0.5 ⁇ 10 mg / L, and preferably 0.5 ⁇ 3mg / L.
- niacin for example, nicotinamide can be preferably used.
- niacin for example, nicotinamide can be preferably used.
- it can be blended in either or both of the first chamber infusion and the second chamber infusion, but is preferably blended in the second chamber infusion.
- the blending ratio of niacin in the second chamber infusion is, for example, 10 to 100 mg / L, preferably 20 to 50 mg / L.
- the concentration of niacin in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 5 to 50 mg / L, preferably 5 to 25 mg / L.
- panthenol can be preferably used.
- pantothenic acid When pantothenic acid is blended, it can be blended in one or both of the first chamber infusion and the second chamber infusion.
- the blending ratio of pantothenic acid is, for example, 5 to 30 mg / L, preferably 10 to 20 mg / L as panthenol.
- the concentration of panthenol in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 2.5 to 15 mg / L, preferably 5 to 10 mg / L.
- biotin When biotin is blended, it can be blended in one or both of the first chamber infusion and the second chamber infusion, but is preferably blended in the second chamber infusion.
- the blending ratio of biotin in the second chamber infusion is, for example, 10 to 100 ⁇ g / L, preferably 20 to 80 ⁇ g / L.
- the concentration of biotin in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 1 to 50 ⁇ g / L, preferably 10 to 40 ⁇ g / L.
- Vitamin A retinol palmitate can be preferably used.
- dissolved this in oil can also be used.
- Vitamin A is a fat-soluble vitamin and is blended into the first chamber infusion.
- the mixing ratio of vitamin A in the first chamber infusion is, for example, 1000 to 5000 IU / L, preferably 2000 to 4000 IU / L.
- the concentration of vitamin A in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 500 to 2500 IU / L, preferably 1000 to 2000 IU / L.
- IU is an international unit (international unit). Also called vitamin A unit.
- Vitamin D As vitamin D, cholecalciferol (vitamin D 3 ) can be preferably used. Vitamin D is a fat-soluble vitamin and is blended in the first chamber infusion.
- the mixing ratio of vitamin D in the first chamber infusion is, for example, 2 to 10 ⁇ g / L, preferably 2.5 to 6 ⁇ g / L.
- the concentration of vitamin D in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 0.5 to 10 ⁇ g / L, preferably 0.5 to 3 ⁇ g / L.
- Vitamin E is a fat-soluble vitamin and is blended into the first chamber infusion.
- the blending ratio of vitamin E in the first chamber infusion is, for example, 2 to 50 mg / L, preferably 5 to 20 mg / L.
- the concentration of vitamin E in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 1 to 25 mg / L, preferably 2.5 to 10 mg / L.
- vitamin K 1 phytonadione
- Vitamin K is a fat-soluble vitamin and is blended into the first chamber infusion.
- the mixing ratio of vitamin K in the first chamber infusion is, for example, 50 to 2500 ⁇ g / L, preferably 80 to 2000 ⁇ g / L.
- the concentration of vitamin K in the mixed solution of the first chamber infusion and the second chamber infusion is, for example, 20 to 1200 ⁇ g / L, preferably 30 to 1000 ⁇ g / L.
- compositions can be illustrated as a preferable example of the active ingredient contained in the first chamber infusion composition and the second chamber infusion composition. It should be noted that at least one selected from the group consisting of a buffering amino acid and a divalent organic acid and a trivalent organic acid is added to the first chamber separately.
- both the first chamber infusion and the second chamber infusion can be manufactured in accordance with a known infusion manufacturing method.
- each infusion component can be produced by dissolving in distilled water for injection.
- the fat-soluble component is preferably used during emulsification, for example, as described above.
- the infusion preparation of the present invention is used by mixing first chamber infusion and second chamber infusion at the time of use.
- the mixed solution of the first chamber infusion and the second chamber infusion has a pH of 6.53 or less, preferably 6.4 or less.
- the pH of the mixed solution is within this range, in combination with other features of the present invention, the generation of insoluble foreign matter after two-component mixing during long-term storage is suppressed.
- generation of free fatty acids in the first infusion during long-term storage is suppressed.
- generation of insoluble foreign matters in the mixed solution due to free fatty acids is suppressed.
- the first chamber infusion is an amino acid having buffering properties such as histidine, a divalent organic acid and a trivalent organic acid. It is important that the feature that the total amount of at least one selected from the group consisting of organic acids is 0.15 g / L or more and the feature that the pH of the mixed solution is 6.53 or less are effectively combined. is there.
- the first chamber infusion contains a buffered amino acid and at least one selected from the group consisting of a divalent organic acid and a trivalent organic acid in a total amount of 0.15 g / L or more, and a mixed solution
- the pH of the aqueous solution should be 6.53 or less, preferably (1) at least one selected from the group consisting of an amino acid having a buffering property, and a divalent organic acid and a trivalent organic acid.
- the first chamber infusion has buffering amino acids, divalent organic acids and trivalent
- the total amount of at least one selected from the group consisting of organic acids is 0.2 g / L or more, and the pH of the mixed solution is 6.4 or less.
- the present inventors have found that the generation of insoluble foreign matters in the mixed liquid caused by free fatty acids occurs specifically when free fatty acids form a salt with Ca 2+ . Therefore, it is desirable that the mixed liquid has a reduced Ca 2+ content ratio in the mixed liquid of the first chamber infusion and the second chamber infusion in order to finally suppress the generation of insoluble foreign matter.
- the Ca 2+ content in the mixed solution of the second chamber infusion is preferably 3 to 6 mEq / L.
- the infusion preparation of the present invention has a titratable acidity of preferably 1 to 10 and an osmotic pressure ratio of preferably 2 to 3.
- the volume ratio between the first chamber infusion and the second chamber infusion is appropriately set according to the liquid volume of the first chamber infusion and the second chamber infusion described above, but is contained. From the viewpoint of the stability of each component and the setting of the osmotic pressure of each chamber, for example, a volume ratio in which the volume ratio of (first chamber infusion: second chamber infusion) is (3: 2 to 3: 5) can be mentioned. .
- the amount of heat in the mixed solution is preferably 450 to 750 kcal / L, more preferably 500 to 650 kcal / L.
- the proportion of fat is preferably 40% or less, more preferably 20 to 40%.
- the ratio of sugar, fat, and amino acid is preferably sugar: 40-60%, fat: 20-40%, amino acid: 10-30%, sugar: 45-55%, More preferably, the fat is 25 to 35%, and the amino acid is 15 to 25%.
- the approximate amount of heat can be obtained by multiplying the blending amount (g) of each component by 4 for sugar, 9 for fat, and 4 for amino acid. That is, the calorie of 1 g of sugar is about 4 kcal, the calorie of 1 g of lipid is about 9 kcal, the calorie of 1 g of amino acid is about 4 kcal, and the calorie can be determined based on this.
- the above description of “amount of heat in the mixture” is based on the value calculated by this calculation.
- composition can be illustrated as a preferable example of a composition of each component in the said liquid mixture.
- the infusion formulation of the present invention is used for the purpose of nutritional management of patients before and after surgery in the case of mild hypoproteinemia or mild undernutrition due to insufficient oral intake, or in the invasive phase.
- it is preferably used for the purpose of nutrition management of patients who are difficult to orally supplement after oral surgery or due to digestive diseases (preferably patients who have undergone surgery for gastrointestinal resection).
- the infusion preparation of the present invention can be administered to a patient for 1 to 14 days after surgery, preferably 1 to 3 days after surgery, the nutritional status of the patient can be maintained healthy.
- the dose and the administration rate can be appropriately set in consideration of the symptoms and age of each patient.
- the infusion preparation of the present invention can keep the nutritional state of a patient healthy only with the infusion preparation during the administration period.
- the infusion preparation of the present invention is preferably administered from a peripheral vein. That is, the infusion preparation of the present invention is preferably an infusion preparation for peripheral vein administration.
- the infusion preparation of the present invention is preferably exhibited.
- the container for storing the infusion solution in the first chamber and the infusion solution in the second chamber is not particularly limited as long as it has two chambers that can communicate with each other.
- various communication means that can be opened in the partition Examples thereof include a two-chamber container (infusion bag) separated by a partition wall that can be communicated, such as the one provided (Japanese Patent Publication No. 63-20550).
- an infusion bag in which the partition wall is formed by an easy peel seal is suitable because it is suitable for mass production and communication work is easy.
- the material of the container include various gas permeable plastics commonly used for medical containers, such as polyethylene, polypropylene, polyvinyl chloride, crosslinked ethylene / vinyl acetate copolymer, ethylene / ⁇ -olefin copolymer.
- gas permeable plastics commonly used for medical containers, such as polyethylene, polypropylene, polyvinyl chloride, crosslinked ethylene / vinyl acetate copolymer, ethylene / ⁇ -olefin copolymer.
- flexible plastics such as blends, blends of these polymers, and laminates.
- Filling and storing the first chamber infusion and the second chamber infusion into the container can be performed according to a conventional method.
- each infusion is filled in each chamber under an inert gas atmosphere, sealed, and heat sterilized. A method is mentioned.
- the heat sterilization can employ a known method such as high-pressure steam sterilization or hot water shower sterilization, and can be performed in an inert gas atmosphere such as carbon dioxide or nitrogen as necessary.
- the infusion preparation of the present invention does not produce insoluble foreign matter when autoclaved at a temperature of 116 ° C. to 121 ° C.
- the first chamber infusion and the second chamber infusion contained in the container are preferably packaged with an oxygen barrier outer packaging bag together with an oxygen scavenger in order to reliably prevent alteration, oxidation and the like.
- an infusion bag in which a partition wall is formed by an easily peelable seal is adopted as a container, the infusion bag is folded at an easily peelable seal portion so that the partition wall does not communicate due to external pressure, for example, an easily peelable seal portion It is preferable that it is packaged in a folded state.
- inert gas filling packaging etc. can also be performed as needed.
- the material of the oxygen barrier outer packaging suitable for the above packaging various commonly used films, sheets, etc. can be used. Specific examples thereof include an ethylene / vinyl alcohol copolymer, polyvinylidene chloride, polyacrylonitrile, polyvinyl alcohol, polyamide, polyester, etc., or a film or sheet made of a material containing at least one of these.
- oxygen scavenger various known materials, for example, those containing iron compounds such as iron hydroxide, iron oxide, and iron carbide as active ingredients, and those using low-molecular phenol and activated carbon may be used. it can.
- Typical commercial product names include “Ageless” (Mitsubishi Gas Chemical Co., Ltd.), “Modulan” (Nippon Kayaku Co., Ltd.), “Secur” (Nippon Soda Co., Ltd.), and “Tamotsu” (Oji Chemical). And “Keypit” (manufactured by Draincy).
- Preparation of infusion formulation Preparation of 1st chamber infusions 1 to 4
- Purified soy oil, purified egg yolk lecithin and glucose were added to water according to the composition shown in Table 2, coarsely emulsified with a homomixer, and then finely emulsified with a high-pressure emulsifier (Manton Gorin).
- L-histidine and water were added to adjust the total amount to 300 ml.
- the pH was adjusted using hydrochloric acid.
- the osmotic pressure ratio of the first chamber infusion thus obtained was 2.9 and the titratable acidity was 1.
- Second Chamber Infusions A to D According to the composition shown in Table 3, amino acids, electrolytes and stabilizers (sodium hydrogen sulfite) were dissolved in distilled water for injection to prepare amino electrolyte solutions. Further, the pH of the solution was adjusted with glacial acetic acid to make a total volume of 250 mL, and a second chamber infusion was prepared. The osmotic pressure ratio of the second chamber infusion thus obtained was 2.7. The concentration in the second chamber infusion was 12.68 mEq / L for citric acid and 10.00 mEq / L for calcium.
- Each of the chamber spaces was replaced with nitrogen, sealed, and then subjected to high-pressure steam sterilization at a set temperature of 116 ° C. and a sterilization time of 26 minutes. Thereafter, the container was folded at an easily peelable seal portion and sealed in an outer bag of a gas barrier film together with an oxygen scavenger to obtain an infusion preparation.
- three same infusion preparations were prepared for each.
- the above-mentioned infusion preparation prepared by filling preparations 1 to 4 as the first chamber infusion and preparation A as the second chamber infusion was stored at 60 ° C./75% RH for 3 weeks.
- the infusion solution and the second chamber infusion solution were mixed, and the presence or absence of insoluble foreign matter was confirmed at each time point immediately after mixing, 26 hours after mixing, and 48 hours after mixing, and the pH at 48 hours after mixing was measured.
- the results are shown in Table 4.
- the infusion preparation filled with the preparation 1 having an L-histidine amount of 0.1 g / L showed the formation of white insoluble foreign matter on the inner surface of the container from 26 hours after mixing.
- the above-mentioned infusion preparation prepared by filling preparations 1 to 4 as the first chamber infusion and preparation B as the second chamber infusion was stored at 60 ° C./75% RH for 3 weeks.
- the infusion solution and the second chamber infusion solution were mixed, and the presence or absence of insoluble foreign matter was confirmed at each time point immediately after mixing, 26 hours after mixing, and 48 hours after mixing, and the pH at 48 hours after mixing was measured. The results are shown in Table 5.
- the infusion preparation filled with the preparation 1 having an L-histidine amount of 0.1 g / L showed the formation of white insoluble foreign matter on the inner surface of the container from 26 hours after mixing.
- white insoluble foreign matter was generated on the inner surface of the container from 26 hours after mixing. Admitted.
- the above-mentioned infusion preparation prepared by filling preparations 1 to 4 as a first chamber infusion and preparation C as a second chamber infusion was stored at 60 ° C./75% RH for 3 weeks.
- the infusion solution and the second chamber infusion solution were mixed, and the presence or absence of insoluble foreign matter was confirmed at each time point immediately after mixing, 26 hours after mixing, and 48 hours after mixing, and the pH at 48 hours after mixing was measured.
- the results are shown in Table 6.
- the pH at the point of 48 hours after mixing was 6 in any case where any infusion of the preparations 1 to 4 was filled as the first chamber infusion. Further, the formation of white insoluble foreign matter was observed on the inner surface of the container from 26 hours after mixing.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
[項1]
連通可能な仕切りにより隔てられた2室を有し、
第1室に脂肪乳剤を含み、さらに緩衝性を有するアミノ酸、並びに二価の有機酸及び三価の有機酸からなる群より選択される少なくとも一種を含む第1室輸液が収容され、かつ
第2室にアミノ酸及び電解質として少なくともカルシウムを含む第2室輸液が収容された輸液製剤であって、
前記第1室輸液における、緩衝性を有するアミノ酸、並びに二価の有機酸及び三価の有機酸の合計含有割合が0.15g/L~0.5g/Lであり、かつ
仕切り連通後48時間の時点における前記第1室輸液及び第2室輸液の混合液のpHが6.53以下である、輸液製剤。
[項2]
前記脂肪乳剤が乳化剤を含み、前記第1室輸液が、前記乳化剤を、0.01~2w/v%含む、項1に記載の輸液製剤。
[項3]
仕切り連通後の前記第1室輸液及び第2室輸液の混合液が、Ca2+を1mEq/L以上含む、項1又は2に記載の輸液製剤。
[項4]
第2室輸液が、電解質としてさらに少なくともクエン酸を含み、第2室輸液において、クエン酸の濃度(mEq)がカルシウムの濃度(mEq)以上である、項1~3のいずれか一項に記載の輸液製剤。
[項5]
第1室輸液が、前記緩衝性を有するアミノ酸として少なくともヒスチジンを含む、項1~4のいずれか一項に記載の輸液製剤。
[項6]
仕切り連通により得られる、項1~5のいずれか一項に記載される前記第1室輸液及び第2室輸液の混合液。
本発明で用いられる第1室輸液は、脂肪乳剤を含み、さらに緩衝性を有するアミノ酸、並びに二価の有機酸及び三価の有機酸からなる群より選択される少なくとも一種を含む。
本発明で用いられる第2室輸液は、アミノ酸及び電解質としてカルシウムを含む。
3室又は4室輸液製剤とせずとも、2室輸液製剤において多種のビタミンを安定に配合できる点も、本発明の輸液製剤の特徴の一つである。ビタミンには水溶性ビタミンと脂溶性ビタミンがある。本発明の輸液製剤では、脂溶性ビタミンは第1室輸液に配合される。また、水溶性ビタミンは、第1室輸液、第2室輸液のいずれに配合されてもよい。但し、前述の通り、ビタミンB1は第1室輸液に配合される。
例えば、第1室輸液に葉酸が配合される場合には、ビタミンB2は第2室輸液に配合されることが望ましい。ビタミンB2が第2室輸液に配合される場合、第2室輸液におけるビタミンB2の配合割合は、リボフラビンとして、例えば2.5~15mg/L、好ましくは4~8mg/Lである。また、本発明の輸液製剤において、第1室輸液と第2室輸液の混合液におけるビタミンB2の濃度は、リボフラビンとして、例えば0.5~10mg/L、好ましくは0.5~3mg/Lである。
ビタミンB6を第1室輸液に配合する場合、第1室輸液におけるビタミンB6の配合割合は、ピリドキシンとして、例えば2~10mg/L、好ましくは2.5~6mg/Lである。また、本発明の輸液製剤において、第1室輸液と第2室輸液の混合液におけるビタミンB6の濃度は、ピリドキシンとして、例えば1~10mg/L、好ましくは1.5~4.5mg/Lである。
ビタミンKは脂溶性ビタミンであり、第1室輸液に配合される。第1室輸液におけるビタミンKの配合割合は、例えば50~2500μg/L、好ましくは80~2000μg/Lである。また、本発明の輸液製剤において、第1室輸液と第2室輸液の混合液におけるビタミンKの濃度は、例えば20~1200μg/L、好ましくは30~1000μg/Lである。
精製大豆油:10-50 g/L
ブドウ糖:70-150 g/L
チアミン塩化物塩酸塩:3-10 mg/L
ピリドキシン塩酸塩:3-7 mg/L
シアノコバラミン:2.5-5μg/L
葉酸:0.2-0.5 mg/L
ビタミンA油:2000-4000 IU/L
コレカルシフェロール:2.5-5μg/L
トコフェロール酢酸エステル:5-20 mg/L
フィトナジオン:80-2000μg/L
パンテノール:10-20mg/L
L-ロイシン:5-15g/L
L-イソロイシン:3-9g/L
L-バリン:3-9g/L
L-リシン塩酸塩:3.5-15g/L
L-トレオニン:1.2-6g/L
L-トリプトファン:0.3-3g/L
L-メチオニン:0.6-4.8g/L
アセチルシステイン:0.13-2.4g/L
L-フェニルアラニン:1.8-9g/L
L-チロシン:0.06-1.2g/L
L-アルギニン:3-12g/L
L-ヒスチジン:1.2-6g/L
L-アラニン:3-9g/L
L-プロリン:1.2-6g/L
L-セリン:0.6-4.2g/L
グリシン:1.2-6g/L
L-アスパラギン酸:0.12-1.8g/L
L-グルタミン酸:0.12-1.8g/L
ナトリウム:40-80mEq/L
カリウム:25-40mEq/L
カルシウム:6-12mEq/L
マグネシウム:5-15mEq/L
塩素:40-80mEq/L
リン:0-20mmoL/L
亜鉛:2.5-15μmol/L
リボフラビンリン酸エステルナトリウム:5-10mg/L
アスコルビン酸:0.1-0.4g/L
ビオチン:20-80μg/L
ニコチン酸アミド:20-50mg/L
本発明の輸液製剤は、用時に、第1室輸液と第2室輸液を混合して使用される。第1室輸液と第2室輸液の混合液は、pHが6.53以下であり、好ましくは6.4以下である。混合液のpHがこの範囲内であると、本発明の他の特徴とも相まって、長期保存時における二液混合後の不溶性異物の発生が抑制される。具体的には、まず、本発明の他の特徴により、長期保存時の第1輸液における遊離脂肪酸の発生が抑制される。さらに、混合液のpHを上記範囲内とすることにより、遊離脂肪酸を原因とする混合液中における不溶性異物の発生が抑制される。
本発明の輸液製剤は、経口摂取不十分で軽度の低蛋白血症又は軽度の低栄養状態にある場合や侵襲期の場合、手術前後の患者の栄養管理の目的で使用され、とりわけ手術後や消化器疾患等によるに経口的に栄養補給が困難な患者(好ましくは、消化器切除の手術を受けた患者)の栄養管理の目的で好適に使用される。本発明の輸液製剤を、手術後1~14日間、好ましくは手術後1~3日間、患者に投与することにより、患者の栄養状態を健全に保持させることができる。投与量及び投与速度は、各患者の症状や年齢等を考慮した上で適宜設定することができる。特に、本発明の輸液製剤は、上記投与期間、当該輸液製剤のみで、患者の栄養状態を健全に保持させることができる。
第1室輸液と第2室輸液を収容する容器としては、連通可能な2室を有するものであれば特に限定されないが、例えば易剥離シールにより隔壁が形成されたもの(特開平2-4671号公報、実開平5-5138号公報等)、室間をクリップで挟むことにより隔壁が形成されたもの(特開昭63-309263号公報等)、隔壁に開封可能な種々の連通手段を設けたもの(特公昭63-20550号公報等)等のように連通可能な隔壁で隔てられた2室容器(輸液バッグ)が挙げられる。これらのうち、隔壁が易剥離シール(イージーピールシール)により形成された輸液バッグが、大量生産に適しており、また連通作業も容易であるので好ましい。また、上記容器の材質としては、医療用容器等に慣用されている各種のガス透過性プラスチック、例えばポリエチレン、ポリプロピレン、ポリ塩化ビニル、架橋エチレン・酢酸ビニル共重合体、エチレン・α-オレフィン共重合体、これら各ポリマーのブレンドや積層体等の柔軟性プラスチックが挙げられる。
1.第1室輸液1~4の調製
表2に示す組成に従い、精製大豆油、精製卵黄レシチン及びブドウ糖を水に加えホモミキサーにより粗乳化後、高圧乳化機(マントンゴーリン)で精乳化し、さらにL-ヒスチジン及び水を加え全量を300mlに調整した。さらに、塩酸を用いてpHを調整した。このようにして得られた第1室輸液の浸透圧比は2.9、滴定酸度は1であった。
表3に示す組成に従って、各アミノ酸、電解質及び安定化剤(亜硫酸水素ナトリウム)を注射用蒸留水に溶解し、アミノ電解質液を調製した。更に、当該液のpHを氷酢酸で調整し、全量250mLとして、第2室輸液を調製した。このようにして得られた第2室輸液の浸透圧比は2.7であった。また第2室輸液における濃度は、クエン酸としては12.68mEq/L、カルシウムとしては10.00mEq/Lであった。
各室が易剥離シールで仕切られたポリエチレン製2室容器の下室に上記で得られた第1室輸液として製剤1~4を、上室に第2室輸液として製剤A~Cをそれぞれ充填し、各室空間部の窒素置換を行い、密封した後、設定温度を116℃、滅菌時間を26分として高圧蒸気滅菌を行った。その後、容器を易剥離シール部で折り畳み、脱酸素剤と共に、ガスバリアフィルムの外装袋に封入し、輸液製剤を得た。なお、同じ輸液製剤はそれぞれ3ケ作成した。
Claims (6)
- 連通可能な仕切りにより隔てられた2室を有し、
第1室に脂肪乳剤を含み、さらに緩衝性を有するアミノ酸、並びに二価の有機酸及び三価の有機酸からなる群より選択される少なくとも一種を含む第1室輸液が収容され、かつ
第2室にアミノ酸及び電解質として少なくともカルシウムを含む第2室輸液が収容された輸液製剤であって、
前記第1室輸液における、緩衝性を有するアミノ酸、並びに二価の有機酸及び三価の有機酸の合計含有割合が0.15g/L~0.5g/Lであり、かつ
仕切り連通後48時間の時点における前記第1室輸液及び第2室輸液の混合液のpHが6.53以下である、輸液製剤。 - 前記脂肪乳剤が乳化剤を含み、前記第1室輸液が、前記乳化剤を、0.01~2w/v%含む、請求項1に記載の輸液製剤。
- 仕切り連通後の前記第1室輸液及び第2室輸液の混合液が、Ca2+を1mEq/L以上含む、請求項1又は2に記載の輸液製剤。
- 第2室輸液が、電解質としてさらに少なくともクエン酸を含み、第2室輸液において、クエン酸の濃度(mEq)がカルシウムの濃度(mEq)以上である、請求項1~3のいずれか一項に記載の輸液製剤。
- 第1室輸液が、前記緩衝性を有するアミノ酸として少なくともヒスチジンを含む、請求項1~4のいずれか一項に記載の輸液製剤。
- 仕切り連通により得られる、請求項1~5のいずれか一項に記載される前記第1室輸液及び第2室輸液の混合液。
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11202008867RA SG11202008867RA (en) | 2018-03-13 | 2019-03-13 | Transfusion preparation |
KR1020207029063A KR20200131280A (ko) | 2018-03-13 | 2019-03-13 | 수액 제제 |
CN201980018762.5A CN111867605B (zh) | 2018-03-13 | 2019-03-13 | 输液制剂 |
US16/980,201 US11890372B2 (en) | 2018-03-13 | 2019-03-13 | Transfusion preparation |
EP19767271.0A EP3766504A4 (en) | 2018-03-13 | 2019-03-13 | Transfusion preparation |
CA3093800A CA3093800A1 (en) | 2018-03-13 | 2019-03-13 | Transfusion preparation |
JP2019538704A JP6647656B1 (ja) | 2018-03-13 | 2019-03-13 | 輸液製剤 |
AU2019234899A AU2019234899A1 (en) | 2018-03-13 | 2019-03-13 | Transfusion preparation |
PH12020551438A PH12020551438A1 (en) | 2018-03-13 | 2020-09-11 | Transfusion preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018045822 | 2018-03-13 | ||
JP2018-045822 | 2018-03-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019176996A1 true WO2019176996A1 (ja) | 2019-09-19 |
Family
ID=67907739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2019/010195 WO2019176996A1 (ja) | 2018-03-13 | 2019-03-13 | 輸液製剤 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11890372B2 (ja) |
EP (1) | EP3766504A4 (ja) |
JP (1) | JP6647656B1 (ja) |
KR (1) | KR20200131280A (ja) |
CN (1) | CN111867605B (ja) |
AU (1) | AU2019234899A1 (ja) |
CA (1) | CA3093800A1 (ja) |
PH (1) | PH12020551438A1 (ja) |
SG (1) | SG11202008867RA (ja) |
TW (1) | TWI794447B (ja) |
WO (1) | WO2019176996A1 (ja) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6320550B2 (ja) | 1980-09-16 | 1988-04-28 | Nitsushoo Kk | |
JPS63309263A (ja) | 1987-06-09 | 1988-12-16 | Otsuka Pharmaceut Factory Inc | 輸液バッグ |
JPH024671A (ja) | 1988-06-10 | 1990-01-09 | Material Eng Tech Lab Inc | 内容物入り容器 |
JPH055138U (ja) | 1990-11-20 | 1993-01-26 | 株式会社大塚製薬工場 | 輸液バツグ |
WO1994025059A1 (en) * | 1993-04-30 | 1994-11-10 | The Green Cross Corporation | Nutritional transfusion for peripheral vein administration |
JPH0881360A (ja) * | 1994-07-13 | 1996-03-26 | Wakamoto Pharmaceut Co Ltd | 安定な脂肪乳剤 |
JPH11343229A (ja) * | 1999-04-09 | 1999-12-14 | Yoshitomi Pharmaceut Ind Ltd | 安定化された脂肪乳剤含有溶液 |
JP2001079064A (ja) * | 1999-09-10 | 2001-03-27 | Welfide Corp | 輸液入り容器 |
JP2001328934A (ja) * | 2000-05-18 | 2001-11-27 | Nipro Corp | 末梢静脈栄養輸液製剤 |
WO2012073891A1 (ja) | 2010-11-29 | 2012-06-07 | 株式会社大塚製薬工場 | 輸液製剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0752243T3 (da) * | 1991-04-26 | 2003-06-16 | Mitsubishi Pharma Corp | Beholder fyldt med infusionsvæsker |
CA2153553A1 (en) | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
US6461633B1 (en) * | 1997-07-25 | 2002-10-08 | Otsuka Pharmaceutical Factory, Inc. | Reducing sugar-containing fat emulsion and a method for its sterilization |
-
2019
- 2019-03-13 CN CN201980018762.5A patent/CN111867605B/zh active Active
- 2019-03-13 TW TW108108432A patent/TWI794447B/zh active
- 2019-03-13 CA CA3093800A patent/CA3093800A1/en active Pending
- 2019-03-13 US US16/980,201 patent/US11890372B2/en active Active
- 2019-03-13 SG SG11202008867RA patent/SG11202008867RA/en unknown
- 2019-03-13 AU AU2019234899A patent/AU2019234899A1/en active Pending
- 2019-03-13 WO PCT/JP2019/010195 patent/WO2019176996A1/ja unknown
- 2019-03-13 KR KR1020207029063A patent/KR20200131280A/ko active Search and Examination
- 2019-03-13 EP EP19767271.0A patent/EP3766504A4/en active Pending
- 2019-03-13 JP JP2019538704A patent/JP6647656B1/ja active Active
-
2020
- 2020-09-11 PH PH12020551438A patent/PH12020551438A1/en unknown
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6320550B2 (ja) | 1980-09-16 | 1988-04-28 | Nitsushoo Kk | |
JPS63309263A (ja) | 1987-06-09 | 1988-12-16 | Otsuka Pharmaceut Factory Inc | 輸液バッグ |
JPH024671A (ja) | 1988-06-10 | 1990-01-09 | Material Eng Tech Lab Inc | 内容物入り容器 |
JPH055138U (ja) | 1990-11-20 | 1993-01-26 | 株式会社大塚製薬工場 | 輸液バツグ |
WO1994025059A1 (en) * | 1993-04-30 | 1994-11-10 | The Green Cross Corporation | Nutritional transfusion for peripheral vein administration |
JPH0881360A (ja) * | 1994-07-13 | 1996-03-26 | Wakamoto Pharmaceut Co Ltd | 安定な脂肪乳剤 |
JPH11343229A (ja) * | 1999-04-09 | 1999-12-14 | Yoshitomi Pharmaceut Ind Ltd | 安定化された脂肪乳剤含有溶液 |
JP2001079064A (ja) * | 1999-09-10 | 2001-03-27 | Welfide Corp | 輸液入り容器 |
JP2001328934A (ja) * | 2000-05-18 | 2001-11-27 | Nipro Corp | 末梢静脈栄養輸液製剤 |
WO2012073891A1 (ja) | 2010-11-29 | 2012-06-07 | 株式会社大塚製薬工場 | 輸液製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3766504A4 |
Also Published As
Publication number | Publication date |
---|---|
TW202002993A (zh) | 2020-01-16 |
JP6647656B1 (ja) | 2020-02-14 |
CA3093800A1 (en) | 2019-09-19 |
AU2019234899A1 (en) | 2020-10-22 |
CN111867605A (zh) | 2020-10-30 |
US11890372B2 (en) | 2024-02-06 |
EP3766504A1 (en) | 2021-01-20 |
JPWO2019176996A1 (ja) | 2020-04-23 |
SG11202008867RA (en) | 2020-10-29 |
US20210007975A1 (en) | 2021-01-14 |
TWI794447B (zh) | 2023-03-01 |
CN111867605B (zh) | 2023-07-25 |
EP3766504A4 (en) | 2021-12-29 |
KR20200131280A (ko) | 2020-11-23 |
PH12020551438A1 (en) | 2021-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6002980B2 (ja) | 輸液製剤 | |
JP6647656B1 (ja) | 輸液製剤 | |
JPH0920650A (ja) | 末梢静脈投与用総合輸液 | |
JP7289137B2 (ja) | 輸液製品 | |
JPH08709A (ja) | 輸液入り容器、輸液製剤及びビタミン配合総合高カロリー輸液製剤 | |
AU2015268572B2 (en) | Infusion preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2019538704 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19767271 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3093800 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20207029063 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2019767271 Country of ref document: EP Effective date: 20201013 |
|
ENP | Entry into the national phase |
Ref document number: 2019234899 Country of ref document: AU Date of ref document: 20190313 Kind code of ref document: A |